Compounds > methyl-p-myristyloxycinnamic acid 1-monoglyceride
Page last updated: 2024-12-11

methyl-p-myristyloxycinnamic acid 1-monoglyceride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6443773
CHEMBL ID346282
MeSH IDM0069146

Synonyms (7)

Synonym
lk 903
CHEMBL346282
2,3-dihydroxypropyl (e)-2-methyl-3-(4-tetradecoxyphenyl)prop-2-enoate
35704-01-9
methyl-p-myristyloxycinnamic acid 1-monoglyceride
lk-903
2-propenoic acid, 2-methyl-3-(4-(tetradecyloxy)phenyl)-, 2,3-dihydroxypropyl ester
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID173720Hypolipidemic activity expressed as percentage decrease in triglyceride in rat, at dosage of 50 mg for 7 days1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID173870Tested for the hypolipidemic activity, expressed as percent decrease in serum cholesterol in rat, at dosage of 50 mg for 7 days1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID173718In vivo hypolipidemic activity, expressed as percent decrease in serum cholesterol in rat, at dosage of 20 mg for 7 days.1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID173725Hypolipidemic activity, expressed as percent decrease in serum cholesterol in rat, at dosage of 100 mg for 7 days by Zak et al method1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID173715In vivo hypolipidemic activity, expressed as percent decrease in Triglyceride in rat, at dosage of 100 mg for 7 days.1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
AID173728In vivo hypolipidemic activity, expressed as percent decrease in serum cholesterol in rat, at dosage of 20 mg for 7 days.1980Journal of medicinal chemistry, Jan, Volume: 23, Issue:1
Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (77.78)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.83 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		1.9610pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		2.6530aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
gemfibrozil
[no description available]		1.9610aromatic etherantilipemic drug
phenobarbital
Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.		1.9510barbituratesanticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative
pirozadil
pirozadil: structure		1.9610trihydroxybenzoic acid
ConditionIndicatedRelationship StrengthStudiesTrials
Liver Steatosis
[description not available]		01.9510
Fatty Liver
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.		01.9510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9610
Hyperlipemia
[description not available]		01.9610
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		01.9610